Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Lung Cancer

Free Subscription Articles published in Clin Cancer Res Retrieve available abstracts of 156 articles: HTML format

Single Articles

September 2026
1. AHN MJ, de Marinis F, Cho BC, Kim TM, et al
   Evaluation of MET Detection Methods and Cutoffs in EGFR-Mutated Non-small Cell Lung Cancer Following Disease Progression on Osimertinib in the phase II SAVANNAH study.
   Clin Cancer Res. 2026 Sep 17. doi: 10.1158/1078-0432.CCR-26-0604.
   PubMed     Abstract available
   
   
   
2. WANG VE, Ward NM, Kratz JR
   Beyond Major Pathologic Response in Lung Cancer: Biomarkers Predict Outcomes.
   Clin Cancer Res. 2026 Sep 17. doi: 10.1158/1078-0432.CCR-26-2536.
   PubMed     Abstract available
   
   
   
3. ZHANG Q, Tang X, Zhang ZF, Velikina R, et al
   Editor's Note: Nicotine Induces Hypoxia-Inducible Factor-1alpha Expression in Human Lung Cancer Cells via Nicotinic Acetylcholine Receptor-Mediated Signaling Pathways.
   Clin Cancer Res. 2026;32:4213.
   PubMed    
   
   
   
4. LI D, Garon EB
   Lessons from Cohort Studies of Targetable Metabolic Deficiencies in Lung Cancer.
   Clin Cancer Res. 2026 Sep 11. doi: 10.1158/1078-0432.CCR-26-2458.
   PubMed     Abstract available
   
   
   
5. MIDDLETON G, Buchanan R, Savage J, De La Mata Chicharro J, et al
   Ceralasertib plus durvalumab in Ras mutant and Ras wild type advanced non-small cell lung cancer: Two cohorts of the phase II platform National Lung Matrix Trial.
   Clin Cancer Res. 2026 Sep 9. doi: 10.1158/1078-0432.CCR-26-1365.
   PubMed     Abstract available
   
   
   
6. MOURI A, Kenmotsu H, Kagamu H, Azuma K, et al
   Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in Patients with Locally Advanced NSCLC.
   Clin Cancer Res. 2026;32:3880-3890.
   PubMed     Abstract available
   
   
   August 2026
7. ZENG J, Cui S, Hippe DS, Fu J, et al
   Mature Outcomes and Patterns of Failure in the Phase II FLARE-RT Trial of Biological Image-Guided and Risk-Adaptive Chemoradiation for Unresectable NSCLC.
   Clin Cancer Res. 2026;32:3434-3443.
   PubMed     Abstract available
   
   
   
8. GARIAZZO E, Elkrief A, Concannon K, Ognissanti D, et al
   Clinical Outcomes and Predictors of Response to PD-(L)1 Blockade in Patients with NSCLC without Actionable Genomic Alterations Who Never Used Tobacco.
   Clin Cancer Res. 2026;32:3683-3693.
   PubMed     Abstract available
   
   
   
9. GUO Q, Deng C, Pan X, Liu J, et al
   A Noninvasive Circulating Tumor DNA Methylation Classifier to Identify Benign Pulmonary Nodules.
   Clin Cancer Res. 2026;32:3629-3640.
   PubMed     Abstract available
   
   
   
10. ROHRBERG KS, Brandao M, Castanon Alvarez E, Felip E, et al
    Rilvegostomig for Metastatic Non-Small-Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study.
    Clin Cancer Res. 2026 Aug 10. doi: 10.1158/1078-0432.CCR-26-0333.
    PubMed     Abstract available
    
    
    July 2026
11. VOKES NI, Symons JL, Rhead B, Hong L, et al
    The genomic landscape and treatment outcomes associated with CDKN2A/MTAP loss in patients with non-small cell lung cancer.
    Clin Cancer Res. 2026 Jul 27. doi: 10.1158/1078-0432.CCR-26-0771.
    PubMed     Abstract available
    
    
    
12. HORIIKE A, Wakui H, Sugawara S, Minegishi Y, et al
    Efficacy and safety of necitumumab and pembrolizumab combination therapy in advanced non-small-cell lung cancer with >/=50% PD-L1 expression: A nonrandomized phase II trial.
    Clin Cancer Res. 2026 Jul 27. doi: 10.1158/1078-0432.CCR-25-2751.
    PubMed     Abstract available
    
    
    
13. NIKNAFS N, Sivapalan L, Balan A, Wehr J, et al
    Landmark ctDNA molecular response represents an early predictor of immunotherapy outcomes in lung cancer: A clinical validity study.
    Clin Cancer Res. 2026 Jul 23. doi: 10.1158/1078-0432.CCR-26-0656.
    PubMed     Abstract available
    
    
    
14. CIPRIANI L, Mascolo D, Scalera S, Bon G, et al
    Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer.
    Clin Cancer Res. 2026 Jul 15. doi: 10.1158/1078-0432.CCR-26-1466.
    PubMed     Abstract available
    
    
    
15. DI FEDERICO A, Pecci F, Jeng M, Peroni M, et al
    Clinical significance of EGFR amplification in patients with EGFR-mutated metastatic non-small cell lung cancer receiving first-line osimertinib.
    Clin Cancer Res. 2026 Jul 14. doi: 10.1158/1078-0432.CCR-26-0924.
    PubMed     Abstract available
    
    
    
16. DALL'OLIO FG, Zrafi W, Vasseur D, Garcia C, et al
    Role of ctDNA Tumor Fraction in Selecting Immunotherapy Based Regimens in Advanced Non-small Cell Lung Cancer.
    Clin Cancer Res. 2026 Jul 13. doi: 10.1158/1078-0432.CCR-25-3917.
    PubMed     Abstract available
    
    
    
17. CHEN M, Li R, Cheng Z, Wei Y, et al
    Divergent Tumor Immune Microenvironment and Response to Neoadjuvant Chemoimmunotherapy in Resectable Non-Small Cell Lung Cancer: A Single-Arm Phase II Trial.
    Clin Cancer Res. 2026 Jul 13. doi: 10.1158/1078-0432.CCR-25-4222.
    PubMed     Abstract available
    
    
    
18. GOLDBERG SB, Ahn MJ, Baik C, De Castro Carpeno J, et al
    Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD.
    Clin Cancer Res. 2026 Jul 13. doi: 10.1158/1078-0432.CCR-26-0704.
    PubMed     Abstract available
    
    
    
19. HUANG J, Aldea M, Miller KW, Rotow JK, et al
    Presenting features and outcomes to standard systemic therapies in patients with MTAP-deleted advanced non-small cell lung cancer.
    Clin Cancer Res. 2026 Jul 6. doi: 10.1158/1078-0432.CCR-26-0188.
    PubMed     Abstract available
    
    
    
20. MARINELLO A, Rotow JK, Lomibao M, Miliziano D, et al
    Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib: Results from the RET-MAP Registry.
    Clin Cancer Res. 2026;32:2637-2643.
    PubMed     Abstract available
    
    
    
21. ANDERS P, Sextro M, Lingelbach K, Standvoss K, et al
    ADC Target Profiling in NSCLC: Generalizable AI Separates TROP-2 and cMET Phenotypes.
    Clin Cancer Res. 2026;32:2765-2786.
    PubMed     Abstract available
    
    
    
22. VISTA WR, Malik V, Sheehan MC, Ismail J, et al
    Irreversible Electroporation Enhances Solid Tumor Infiltration and Selective Cancer Cell Lysis by CAR T Cells.
    Clin Cancer Res. 2026;32:2708-2721.
    PubMed     Abstract available
    
    
    June 2026
23. BORGHAEI H, Balli D, Paz-Ares LG, Reck M, et al
    Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2026 Jun 26:OF1-OF14. doi: 10.1158/1078-0432.CCR-25-0942.
    PubMed     Abstract available
    
    
    
24. JIMENEZ M, Hatton BA, Moreno-Gonzalez A, Iding JS, et al
    Pulsed Electric Field Ablation Reprograms Tumor Immunity and Stimulates Germinal Center Formation in Tertiary Lymphoid Structures in Patients with Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2026 Jun 17. doi: 10.1158/1078-0432.CCR-25-3847.
    PubMed     Abstract available
    
    
    
25. ZENG Z, Huang W, Zeng F, Xiong L, et al
    The Efficacy and Safety of Tislelizumab plus Anlotinib as First-line Treatment in Advanced Pulmonary Sarcomatoid Carcinoma: A Single-Arm Phase II Trial.
    Clin Cancer Res. 2026;32:2372-2380.
    PubMed     Abstract available
    
    
    
26. RUGE L, John F, Verheyen M, Riedel R, et al
    Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS Q61 mutations to assess therapeutic responses.
    Clin Cancer Res. 2026 Jun 10. doi: 10.1158/1078-0432.CCR-26-0133.
    PubMed     Abstract available
    
    
    May 2026
27. NINOMIYA T, Fang C, Hamano H, Morinaga T, et al
    Incidence of B cell malignancies in patients with lung cancer receiving PD-1 blockade therapy.
    Clin Cancer Res. 2026 May 18. doi: 10.1158/1078-0432.CCR-25-3406.
    PubMed     Abstract available
    
    
    
28. LEE EJ, Ko JA, Kim MJ, Cho JS, et al
    JIN-A02, a Mutant-Selective Fourth-Generation EGFR Inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLC.
    Clin Cancer Res. 2026;32:1835-1845.
    PubMed     Abstract available
    
    
    April 2026
29. HASHMI A, Linford J, Chauhan PS, Parikh K, et al
    Early ctDNA stratifies survival in locally advanced and oligometastatic lung cancer treated with radiotherapy.
    Clin Cancer Res. 2026 Apr 30. doi: 10.1158/1078-0432.CCR-25-4983.
    PubMed     Abstract available
    
    
    
30. LEE JB, Kim DK, Lee SH, Kim KH, et al
    A Phase 2 Study of Stereotactic Ablative Radiotherapy Plus Atezolizumab Plus Tiragolumab in Treatment-naive Patients with Advanced Non-small Cell Lung Cancer.
    Clin Cancer Res. 2026 Apr 20. doi: 10.1158/1078-0432.CCR-25-4990.
    PubMed     Abstract available
    
    
    
31. THURSBY SJ, Jin Z, Blum J, Gurau A, et al
    Epigenetic Instability-Based Metrics in Cell-Free DNA for Early Cancer Detection.
    Clin Cancer Res. 2026;32:1528-1539.
    PubMed     Abstract available
    
    
    
32. GRAY JE, Neal JW, Patel JD, Liu SV, et al
    First-Line Sacituzumab Govitecan Plus Pembrolizumab and Carboplatin in Metastatic Non-Small Cell Lung Cancer: Nonsquamous and Squamous Cohorts of the EVOKE-02 Study.
    Clin Cancer Res. 2026 Apr 10. doi: 10.1158/1078-0432.CCR-25-4485.
    PubMed     Abstract available
    
    
    
33. GARRALDA E, Markert C, Moreno V, Calvo E, et al
    A first-in-human phase 1 clinical trial evaluating clinical activity and proof-of-mechanism of tobemstomig, a PD1-LAG3 bispecific antibody, in patients with CPI-experienced melanoma.
    Clin Cancer Res. 2026 Apr 7. doi: 10.1158/1078-0432.CCR-25-4478.
    PubMed     Abstract available
    
    
    March 2026
34. HUANG B, Zhao J, Zhu J, Wang X, et al
    Low-dose intestinal irradiation enhances the efficacy and prognosis of PD-1 blockade in metastatic non-small cell lung cancer.
    Clin Cancer Res. 2026 Mar 18. doi: 10.1158/1078-0432.CCR-25-4153.
    PubMed     Abstract available
    
    
    
35. FUKUMURA K, Jiang P, Yeboa DN, Singareeka Raghavendra A, et al
    Ionizing radiation enhances prognostically significant cellular immunity programs in the brain metastasis microenvironment.
    Clin Cancer Res. 2026 Mar 12. doi: 10.1158/1078-0432.CCR-25-3525.
    PubMed     Abstract available
    
    
    
36. SIERRA-RODERO B, Gil-Gonzalez A, Molina-Alejandre M, Nadal E, et al
    Decoding B Cell Signatures of Complete Pathological Response to Perioperative Chemoimmunotherapy in Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2026 Mar 10. doi: 10.1158/1078-0432.CCR-25-3315.
    PubMed     Abstract available
    
    
    
37. GRAY JE, Laktionov K, Kim SW, Kato T, et al
    Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2026 Mar 9. doi: 10.1158/1078-0432.CCR-25-3431.
    PubMed     Abstract available
    
    
    
38. YU HA, Tang KH, Markovets AA, Hartmaier R, et al
    Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Post-Progression on First-Line Osimertinib: Phase II ORCHARD Study.
    Clin Cancer Res. 2026 Mar 6. doi: 10.1158/1078-0432.CCR-25-4540.
    PubMed     Abstract available
    
    
    
39. WU X, Sun K, Zhang J, Hou S, et al
    Locus-specific human endogenous retrovirus ERVK18 expression indicates an inflamed microenvironment and favorable immunotherapy outcome in small cell lung cancer.
    Clin Cancer Res. 2026 Mar 5. doi: 10.1158/1078-0432.CCR-25-3302.
    PubMed     Abstract available
    
    
    
40. IRAJIZAD E, Fahrmann JF, Wu R, Rudsari H, et al
    Association of blood levels of forever plastics with lung cancer mortality among ever smokers in the Prostate Lung Colorectal and Ovarian (PLCO) cohort study.
    Clin Cancer Res. 2026 Mar 4. doi: 10.1158/1078-0432.CCR-25-3846.
    PubMed     Abstract available
    
    
    February 2026
41. CHEN M, Bulat I, Maglakelidze M, Li N, et al
    Subcutaneously Administered Tislelizumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Pharmacokinetics and Safety Results from the BGB-A317-103 Phase I Study.
    Clin Cancer Res. 2026 Feb 11. doi: 10.1158/1078-0432.CCR-25-2173.
    PubMed     Abstract available
    
    
    January 2026
42. LIU Y, Nashed J, Barone AK, Yuan M, et al
    FDA Approval Summary: Tarlatamab for the Treatment of Extensive Stage Small Cell Lung Cancer.
    Clin Cancer Res. 2026 Jan 26. doi: 10.1158/1078-0432.CCR-25-2287.
    PubMed     Abstract available
    
    
    
43. PFEIL AJ, Zhang T, Cheng R, Mattar MS, et al
    RRAS and RRAS2 mutations are recurrent oncogenic drivers in lung cancer and are sensitive to the pan-RAS inhibitor RMC-6236.
    Clin Cancer Res. 2026 Jan 16. doi: 10.1158/1078-0432.CCR-25-2734.
    PubMed     Abstract available
    
    
    
44. PROVENCIO M, Serna-Blasco R, Nadal E, Gonzalez Larriba JL, et al
    Minimal Residual Disease Enhances Prognostic Stratification Beyond Pathological Response in Resectable Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2026 Jan 15. doi: 10.1158/1078-0432.CCR-25-2958.
    PubMed     Abstract available
    
    
    December 2025
45. JOHN F, Ruge L, Verheyen M, Scharpenseel H, et al
    Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS G12V mutations.
    Clin Cancer Res. 2025 Dec 19. doi: 10.1158/1078-0432.CCR-25-2581.
    PubMed     Abstract available
    
    
    
46. ARMSTRONG AJ, Dietz H, Balli D, Geese WJ, et al
    LRP1b Loss Predicts Sensitivity to Immunotherapy in Patients with NSCLC: An Analysis of the Phase III CheckMate-026 Randomized Trial.
    Clin Cancer Res. 2025;31:5198-5210.
    PubMed     Abstract available
    
    
    November 2025
47. BALASUBRAMANIAN A, Marceaux C, Kanwal S, Tarasova I, et al
    Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial.
    Clin Cancer Res. 2025;31:4644-4654.
    PubMed     Abstract available
    
    
    
48. PECCI F, Li H, Di Federico A, Wu J, et al
    First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy +/- Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC.
    Clin Cancer Res. 2025;31:4802-4813.
    PubMed     Abstract available
    
    
    
49. YANG Y, Nilsson MB, Yu X, Poteete A, et al
    The Activity of EGFR CAR NK and CAR T Cells against EGFR Inhibitor-Resistant NSCLC and Drug-Tolerant Persister Cells.
    Clin Cancer Res. 2025;31:4745-4762.
    PubMed     Abstract available
    
    
    October 2025
50. CHONG CR, Bahcall M, Capelletti M, Kosaka T, et al
    Editor's Note: Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.
    Clin Cancer Res. 2025;31:4384.
    PubMed    
    
    
    September 2025
51. GIUDICE AM, Matlaga S, Roth SL, Gladney W, et al
    D3-GPC2-directed CAR T cells are safe and efficacious in preclinical models of neuroblastoma and small cell lung cancer.
    Clin Cancer Res. 2025 Sep 30. doi: 10.1158/1078-0432.CCR-25-0089.
    PubMed     Abstract available
    
    
    
52. CHEN PW, Minocha M, Kong S, Jiang T, et al
    Tarlatamab exposure-efficacy and exposure-safety relationships to inform dose selection in patients with small cell lung cancer (SCLC).
    Clin Cancer Res. 2025 Sep 10. doi: 10.1158/1078-0432.CCR-25-2134.
    PubMed     Abstract available
    
    
    August 2025
53. RIMNER A, Lok BH, Gelblum DY, Kotecha RR, et al
    Phase I Dose Escalation Trial Combining Olaparib and Thoracic Radiation Therapy in Extensive-Stage Small Cell Lung Cancer.
    Clin Cancer Res. 2025 Aug 29. doi: 10.1158/1078-0432.CCR-24-4342.
    PubMed     Abstract available
    
    
    
54. GAO R, Lou N, Yang S, Yang M, et al
    Multi-Omics and Single-Cell Insights Reveal a Lysophosphatidic Acid (LPA)-Mediated Resistant Mechanism to Third Generation EGFR-TKI in Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2025 Aug 25. doi: 10.1158/1078-0432.CCR-25-0993.
    PubMed     Abstract available
    
    
    
55. CIARDULLO C, Tobalina L, Carr TH, Szekeres P, et al
    Early ctDNA dynamics inform first-line therapy in patients with extensive-stage small cell lung cancer.
    Clin Cancer Res. 2025 Aug 11. doi: 10.1158/1078-0432.CCR-25-2011.
    PubMed     Abstract available
    
    
    July 2025
56. ZHAO L, Pang Y, Ding Y, Chen J, et al
    68Ga-NK224 PET/CT for Noninvasive Evaluation of PD-L1 Expression and Intertumor Heterogeneity: A Translational Exploratory Study.
    Clin Cancer Res. 2025;31:2989-3001.
    PubMed     Abstract available
    
    
    
57. ROLFO C, O'Brate A, Menzel C, Bruns R, et al
    Liquid and Tissue Biopsies for Identifying MET Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib.
    Clin Cancer Res. 2025;31:2675-2684.
    PubMed     Abstract available
    
    
    
58. JANG HJ, Patel M, Wang DY, Kang SW, et al
    Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma.
    Clin Cancer Res. 2025;31:2639-2654.
    PubMed     Abstract available
    
    
    June 2025
59. GAY CM, Owonikoko TK, Byers LA, Choudhury NJ, et al
    Multidimensional Analysis of B7 homolog 3 (B7-H3) RNA Expression in Small-cell Lung Cancer Molecular Subtypes.
    Clin Cancer Res. 2025 Jun 24. doi: 10.1158/1078-0432.CCR-24-3981.
    PubMed     Abstract available
    
    
    
60. DAVAR D, Eroglu Z, Milhem M, Becerra C, et al
    Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer: AMBER Part 2B.
    Clin Cancer Res. 2025 Jun 24:OF1-OF9. doi: 10.1158/1078-0432.CCR-25-0806.
    PubMed     Abstract available
    
    
    
61. DAVIES KD
    Finding Rearrangements in the Cell-Free DNA Haystack.
    Clin Cancer Res. 2025;31:2264-2266.
    PubMed     Abstract available
    
    
    
62. PAWELETZ CP, Urvalek A, Ha M, Garg K, et al
    Round-Robin Comparison of RET Rearrangement Detection in ctDNA: A Novel Method for Limited Clinical Samples.
    Clin Cancer Res. 2025;31:2406-2412.
    PubMed     Abstract available
    
    
    
63. MACK PC, Redman MW, Tukachinsky H, Kozono DE, et al
    Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: a Lung-MAP Study.
    Clin Cancer Res. 2025 Jun 4. doi: 10.1158/1078-0432.CCR-24-3658.
    PubMed     Abstract available
    
    
    
64. ANDREWS HS, Zariffa N, Nishimura KK, Choi SH, et al
    ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials.
    Clin Cancer Res. 2025;31:2162-2172.
    PubMed     Abstract available
    
    
    May 2025
65. CHENG Y, Wang J, Yu Y, Wang Q, et al
    Phase I/II Study of Tifcemalimab, an Anti-B and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer.
    Clin Cancer Res. 2025 May 16. doi: 10.1158/1078-0432.CCR-25-0022.
    PubMed     Abstract available
    
    
    April 2025
66. ZHANG J, Jin Y, Lin H, Deng J, et al
    Amplification of extrachromosomal MYC paralogs shapes immunosuppressive tumor microenvironment in small cell lung cancer.
    Clin Cancer Res. 2025 Apr 29. doi: 10.1158/1078-0432.CCR-24-3399.
    PubMed     Abstract available
    
    
    
67. HIRSCH FR
    Antibody Drug Conjugates in Non-Small Cell Lung Cancer: Where is the Target and the Biomarker?
    Clin Cancer Res. 2025 Apr 28. doi: 10.1158/1078-0432.CCR-25-0839.
    PubMed     Abstract available
    
    
    
68. ZHOU J, Muluneh B, Wang Z, Yao H, et al
    Leveraging Longitudinal Patient-Reported Outcomes Trajectories to Predict Survival in Non-Small-Cell Lung Cancer.
    Clin Cancer Res. 2025 Apr 24. doi: 10.1158/1078-0432.CCR-25-0292.
    PubMed     Abstract available
    
    
    
69. PECCI F, Thummalapalli R, Alden SL, Ricciuti B, et al
    Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2025 Apr 18:OF1-OF13. doi: 10.1158/1078-0432.CCR-24-2990.
    PubMed     Abstract available
    
    
    
70. JENG MY, Schoenfeld AJ
    Can Longitudinal Biomarkers Guide Treatment Decisions? Time Will Tell.
    Clin Cancer Res. 2025;31:1381-1382.
    PubMed     Abstract available
    
    
    
71. MAZZASCHI G, Marrocchio C, Moron Dalla Tor L, Leo L, et al
    Longitudinal Blood Immune-Inflammatory and Radiomic Profiling to Decode Different Patterns of Acquired Resistance to Immunotherapy in Patients with NSCLC.
    Clin Cancer Res. 2025;31:1533-1545.
    PubMed     Abstract available
    
    
    March 2025
72. KANDA S, Niho S, Kurata T, Nomura S, et al
    Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-doublet Chemotherapy for Non-small Cell Lung Cancer Harboring EGFR Mutation.
    Clin Cancer Res. 2025 Mar 31. doi: 10.1158/1078-0432.CCR-24-3532.
    PubMed     Abstract available
    
    
    
73. KATAYAMA Y, Yamada T, Tanimura K, Kawachi H, et al
    YAP Regulates HER3 Signaling-Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers.
    Clin Cancer Res. 2025;31:1127-1141.
    PubMed     Abstract available
    
    
    
74. TRONTZAS IP, He M, Wurtz A, Robbins CJ, et al
    Quantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wild-Type Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2025 Mar 6. doi: 10.1158/1078-0432.CCR-24-3347.
    PubMed     Abstract available
    
    
    February 2025
75. CHENG H, Janakiram M, Borczuk A, Lin J, et al
    Editor's Note: HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status.
    Clin Cancer Res. 2025;31:788.
    PubMed    
    
    
    
76. WOJTALLA A, Fischer B, Kotelevets N, Mauri FA, et al
    Correction: Targeting the Phosphoinositide 3-Kinase p110-alpha Isoform Impairs Cell Proliferation, Survival, and Tumor Growth in Small Cell Lung Cancer.
    Clin Cancer Res. 2025;31:787.
    PubMed    
    
    
    
77. AGGARWAL RK, Sidoli S, Wang J, Sahu S, et al
    Smoking-Associated Carcinogen-Induced Inflammation Promotes Lung Carcinogenesis via IRAK4 Activation.
    Clin Cancer Res. 2025;31:746-755.
    PubMed     Abstract available
    
    
    
78. KOBOLD S
    RORing CAR T Cells in Solid and Hematologic Cancers: Same but Different.
    Clin Cancer Res. 2025;31:437-438.
    PubMed     Abstract available
    
    
    
79. JAEGER-RUCKSTUHL CA, Specht JM, Voutsinas JM, MacMillan HR, et al
    Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies.
    Clin Cancer Res. 2025;31:503-514.
    PubMed     Abstract available
    
    
    January 2025
80. CHIU CL, Zhang D, Zhao H, Wei Y, et al
    Targeting AXL inhibits the growth and metastasis of prostate cancer in bone.
    Clin Cancer Res. 2025 Jan 29. doi: 10.1158/1078-0432.CCR-24-3028.
    PubMed     Abstract available
    
    
    
81. ZHANG JT, Liu SY, Gao X, Liu SM, et al
    Follow-Up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2025 Jan 24. doi: 10.1158/1078-0432.CCR-24-2909.
    PubMed     Abstract available
    
    
    
82. KATO R, Solanki HS, Ozakinci H, Desai B, et al
    In situ RAS:RAF binding correlates with response to KRASG12C inhibitors in KRASG12C--mutant non-small cell lung cancer.
    Clin Cancer Res. 2025 Jan 21. doi: 10.1158/1078-0432.CCR-24-3714.
    PubMed     Abstract available
    
    
    
83. CAPPUZZO F, Ricciuti B, Delmonte A, Bonanno L, et al
    MAPK pathway activating alteration and immunotherapy efficacy in squamous cell lung carcinoma: results from the randomized, prospective SQUINT trial.
    Clin Cancer Res. 2025 Jan 21. doi: 10.1158/1078-0432.CCR-24-2077.
    PubMed     Abstract available
    
    
    
84. SMEENK MM, van Diessen JNA, Boellaard TN, Hartemink KJ, et al
    Tremelimumab plus durvalumab prior to chemoradiotherapy in unresectable, locally advanced non-small cell lung cancer: the Induction trial.
    Clin Cancer Res. 2025 Jan 17. doi: 10.1158/1078-0432.CCR-24-3476.
    PubMed     Abstract available
    
    
    
85. ROSNER S, Connor S, Sanber K, Zahurak M, et al
    Divergent Clinical and Immunologic Outcomes Based on STK11 Co-mutation Status in Resectable KRAS-Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade.
    Clin Cancer Res. 2025;31:339-351.
    PubMed     Abstract available
    
    
    
86. REINECKE JB, Jimenez Garcia L, Gross AC, Cam M, et al
    Aberrant Activation of Wound-Healing Programs within the Metastatic Niche Facilitates Lung Colonization by Osteosarcoma Cells.
    Clin Cancer Res. 2025;31:414-429.
    PubMed     Abstract available
    
    
    
87. DALL'OLIO FG, Zrafi W, Roelants V, Ambrosini V, et al
    Metabolic Tumor Volume Assessed by 18F FDG-PET CT Scan as a Predictive Biomarker for Immune Checkpoint Blockers in Advanced NSCLC and Its Biological Correlates.
    Clin Cancer Res. 2025;31:352-364.
    PubMed     Abstract available
    
    
    
88. NEGRAO MV, Paula AG, Molkentine D, Hover L, et al
    Impact of co-mutations and transcriptional signatures in non-small cell lung cancer patients treated with adagrasib in the KRYSTAL-1 trial.
    Clin Cancer Res. 2025 Jan 13. doi: 10.1158/1078-0432.CCR-24-2310.
    PubMed     Abstract available
    
    
    
89. MEADOR CB, Digumarthy SR, Yeap BY, Hung YP, et al
    Phase I/II Investigator-Initiated Study of Olaparib and Temozolomide in SCLC: Final Analysis and CNS Outcomes.
    Clin Cancer Res. 2025;31:25-34.
    PubMed     Abstract available
    
    
    
90. SCHULER M
    Facts and hopes in neoadjuvant immunotherapy combinations in resectable non-small-cell lung cancer.
    Clin Cancer Res. 2025 Jan 2. doi: 10.1158/1078-0432.CCR-24-1441.
    PubMed     Abstract available
    
    
    December 2024
91. LEE S, Hamid O, Jotte R, Zakharia Y, et al
    Phase 2 Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1 Pretreated Metastatic Non-Small Cell Lung Cancer and Metastatic Cutaneous Melanoma.
    Clin Cancer Res. 2024 Dec 30. doi: 10.1158/1078-0432.CCR-24-1478.
    PubMed     Abstract available
    
    
    
92. AOKAGE K, Koyama S, Kumagai S, Nomura K, et al
    Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1-Positive NSCLC: A Phase II Trial (EAST ENERGY).
    Clin Cancer Res. 2024;30:5584-5592.
    PubMed     Abstract available
    
    
    
93. SCHULTZ KAP, Nelson AT, Mallinger PHR, Harris AK, et al
    DICER1-Related Tumor Predisposition: Identification of At-risk Individuals and Recommended Surveillance Strategies.
    Clin Cancer Res. 2024;30:5681-5692.
    PubMed     Abstract available
    
    
    
94. VON ITZSTEIN MS, Burns TF, Dowell JE, Horn L, et al
    Phase 1/2 trial of XPO1 inhibitor selinexor plus docetaxel in previously treated, advanced KRAS mutant non-small cell lung cancer.
    Clin Cancer Res. 2024 Dec 9. doi: 10.1158/1078-0432.CCR-24-1722.
    PubMed     Abstract available
    
    
    November 2024
95. ALTAN M, Lopes G, Hiltermann TJN, Govindan R, et al
    Safety and Tolerability of Letetresgene Autoleucel (Lete-cel; GSK3377794): Pilot Studies in Patients With Advanced Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2024 Nov 22. doi: 10.1158/1078-0432.CCR-24-1591.
    PubMed     Abstract available
    
    
    
96. SOO RA, Dafni U, Han JY, Cho BC, et al
    ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial.
    Clin Cancer Res. 2024;30:5180-5191.
    PubMed     Abstract available
    
    
    October 2024
97. STEWART CA, Diao L, Xi Y, Wang R, et al
    YAP1 Status Defines Two Intrinsic Subtypes of LCNEC with Distinct Molecular Features and Therapeutic Vulnerabilities.
    Clin Cancer Res. 2024;30:4743-4754.
    PubMed     Abstract available
    
    
    
98. VERKERK K, van der Wel TJWT, Zeverijn LJ, Geurts BS, et al
    Safety, Efficacy and Biomarker Analysis of Crizotinib in MET Mutated Non-Small Cell Lung Cancer - Results from the Drug Rediscovery Protocol.
    Clin Cancer Res. 2024 Oct 1. doi: 10.1158/1078-0432.CCR-24-1925.
    PubMed     Abstract available
    
    
    
99. LIZARDO MM, Hughes C, Huang YZ, Shyp T, et al
    Pharmacologic Inhibition of EIF4A Blocks NRF2 Synthesis to Prevent Osteosarcoma Metastasis.
    Clin Cancer Res. 2024;30:4464-4481.
    PubMed     Abstract available
    
    
    September 2024
100. MORGENSZTERN D, Ready N, Johnson ML, Dowlati A, et al
     A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients With Small Cell Lung Cancer.
     Clin Cancer Res. 2024 Sep 17. doi: 10.1158/1078-0432.CCR-24-1547.
     PubMed     Abstract available
     
     
     
101. VOKES NI, Le X, Yap TA
     PIKing up and AKTing on Resistance Mutations in Osimertinib-Treated EGFR-Mutated NSCLC.
     Clin Cancer Res. 2024;30:3968-3970.
     PubMed     Abstract available
     
     
     
102. CHOI Y, Dharia NV, Jun T, Chang J, et al
     Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors.
     Clin Cancer Res. 2024;30:3788-3797.
     PubMed     Abstract available
     
     
     
103. EL ZARIF T, Meador CB, Qiu X, Seo JH, et al
     Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling.
     Clin Cancer Res. 2024;30:3798-3811.
     PubMed     Abstract available
     
     
     August 2024
104. KOBAN MU, Hartmann M, Amexis G, Franco P, et al
     Targeted therapies, novel antibodies, and immunotherapies in advanced non-small cell lung cancer: clinical evidence and drug approval patterns.
     Clin Cancer Res. 2024 Aug 23. doi: 10.1158/1078-0432.CCR-24-0741.
     PubMed     Abstract available
     
     
     
105. OH S, Koh J, Kim TM, Kim S, et al
     Transcriptomic heterogeneity of EGFR-mutant non-small cell lung cancer evolution towards small cell lung cancer.
     Clin Cancer Res. 2024 Aug 16. doi: 10.1158/1078-0432.CCR-24-0160.
     PubMed     Abstract available
     
     
     July 2024
106. REINMUTH N, Juan-Vidal O, Kowalski D, Bryl M, et al
     Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small-Cell Lung Cancer: The Phase II BALTIC Study.
     Clin Cancer Res. 2024 Jul 17. doi: 10.1158/1078-0432.CCR-24-0013.
     PubMed     Abstract available
     
     
     
107. SUVILESH KN, Manjunath Y, Nussbaum YI, Gadelkarim M, et al
     Targeting AKR1B10 by drug repurposing with epalrestat overcomes chemoresistance in non-small cell lung cancer patient-derived tumor organoids.
     Clin Cancer Res. 2024 Jul 17. doi: 10.1158/1078-0432.CCR-23-3980.
     PubMed     Abstract available
     
     
     
108. SCALERA S, Ricciuti B, Marinelli D, Mazzotta M, et al
     Transcriptional phenocopies of deleterious KEAP1 mutations correlate with survival outcomes in lung cancer treated with immunotherapy.
     Clin Cancer Res. 2024 Jul 9. doi: 10.1158/1078-0432.CCR-24-0626.
     PubMed     Abstract available
     
     
     
109. YANG SR, Jayakumaran G, Benhamida J, Febres-Aldana CA, et al
     Diffuse Pleural Mesotheliomas with Genomic Near-Haploidization: A Newly Recognized Subset with Distinct Clinical, Histologic, and Molecular Features.
     Clin Cancer Res. 2024;30:2780-2789.
     PubMed     Abstract available
     
     
     June 2024
110. CHOUDHURY NJ, Lai WV, Makhnin A, Heller G, et al
     A phase I/II study of valemetostat (DS-3201b), an EZH1/2 inhibitor, in combination with irinotecan in patients with recurrent small cell lung cancer.
     Clin Cancer Res. 2024 Jun 28. doi: 10.1158/1078-0432.CCR-23-3383.
     PubMed     Abstract available
     
     
     
111. BARBATO MI, Bradford D, Ren Y, Aungst SL, et al
     FDA Approval Summary: Repotrectinib for locally advanced or metastatic ROS1-positive non-small cell lung cancer.
     Clin Cancer Res. 2024 Jun 14. doi: 10.1158/1078-0432.CCR-24-0949.
     PubMed     Abstract available
     
     
     
112. PANG L, Huang Y, Zhuang W, Zhang Y, et al
     Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC.
     Clin Cancer Res. 2024;30:2636-2646.
     PubMed     Abstract available
     
     
     
113. DALAL B, Tada T, Patel DP, Pine SR, et al
     Urinary Metabolite Diagnostic and Prognostic Liquid Biopsy Biomarkers of Lung Cancer in Non-smokers and Tobacco Smokers.
     Clin Cancer Res. 2024 Jun 5. doi: 10.1158/1078-0432.CCR-24-0637.
     PubMed     Abstract available
     
     
     
114. ROLFO CD, Madison RW, Pasquina LW, Brown DW, et al
     Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation.
     Clin Cancer Res. 2024;30:2452-2460.
     PubMed     Abstract available
     
     
     May 2024
115. FUKUDA A, Okuma Y
     From Rarity to Reality: Osimertinib's Promising Horizon in Treating Uncommon EGFR Mutations in Non-Small Cell Lung Cancer.
     Clin Cancer Res. 2024 May 20. doi: 10.1158/1078-0432.CCR-23-4035.
     PubMed     Abstract available
     
     
     
116. PENG X, Zhao H, Ye L, Hou F, et al
     Biomarker identification and risk prediction model development for differentiated thyroid carcinoma lung metastasis based on primary lesion proteomics.
     Clin Cancer Res. 2024 May 9. doi: 10.1158/1078-0432.CCR-23-3806.
     PubMed     Abstract available
     
     
     
117. REKHTMAN N
     All That Is Small Is Not a Small-Cell Carcinoma: Thoracic SMARCA4-Deficient Undifferentiated Tumors Masquerading as SCLC.
     Clin Cancer Res. 2024;30:1708-1711.
     PubMed     Abstract available
     
     
     
118. MARINIELLO A, Nasti TH, Chang DY, Hashimoto M, et al
     Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade.
     Clin Cancer Res. 2024;30:1833-1845.
     PubMed     Abstract available
     
     
     April 2024
119. ZHOU R, Liu F, Zhang H, Wang D, et al
     Fraction dose escalation of hypofractionated radiotherapy with concurrent chemotherapy and subsequent consolidation immunotherapy in locally advanced non-small cell lung cancer: a phase 1 study.
     Clin Cancer Res. 2024 Apr 23. doi: 10.1158/1078-0432.CCR-23-3600.
     PubMed     Abstract available
     
     
     
120. ZUGAZAGOITIA J, Osma H, Baena J, Ucero AC, et al
     Facts and hopes on cancer immunotherapy for small cell lung cancer.
     Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-23-1159.
     PubMed     Abstract available
     
     
     
121. PERESSINI M, Garcia-Campelo R, Massuti B, Marti C, et al
     Spatially preserved multi-region transcriptomic subtyping and biomarkers of chemoimmunotherapy outcome in extensive-stage small cell lung cancer.
     Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-24-0104.
     PubMed     Abstract available
     
     
     
122. GRAZINI U, Markovets A, Ireland L, O'Neill D, et al
     Overcoming osimertinib resistance with AKT inhibition in EGFRm-driven Non-Small-Cell-Lung-Cancer with PIK3CA/PTEN alterations.
     Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-23-2540.
     PubMed     Abstract available
     
     
     
123. OH HJ, Bae SC, Oh IJ, Park CK, et al
     Nicotinamide in Combination with EGFR-TKIs for the Treatment of Stage IV Lung Adenocarcinoma with EGFR Mutations: A Randomized Double-Blind (Phase IIb) Trial.
     Clin Cancer Res. 2024;30:1478-1487.
     PubMed     Abstract available
     
     
     
124. LEE EJ, Oh SY, Lee YW, Kim JY, et al
     Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC.
     Clin Cancer Res. 2024;30:1582-1594.
     PubMed     Abstract available
     
     
     
125. SINGH AK, Lewis CD, Boas CAWV, Diebolder P, et al
     Development of a [89Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library.
     Clin Cancer Res. 2024;30:1293-1306.
     PubMed     Abstract available
     
     
     
126. VAIDYA P, Cohen EEW
     Facts and Hopes in Neoadjuvant Immunotherapy: Current Approvals and Emerging Evidence.
     Clin Cancer Res. 2024;30:1232-1239.
     PubMed     Abstract available
     
     
     February 2024
127. ZHOU I, Plana D, Palmer AC
     Tumor-Specific Activity of Precision Medicines in the NCI-MATCH Trial.
     Clin Cancer Res. 2024;30:786-792.
     PubMed     Abstract available
     
     
     
128. KASI PM, Lee JK, Pasquina LW, Decker B, et al
     Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types.
     Clin Cancer Res. 2024;30:836-848.
     PubMed     Abstract available
     
     
     
129. WEI D, Wang L, Zuo X, Maitra A, et al
     A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer.
     Clin Cancer Res. 2024;30:655-662.
     PubMed     Abstract available
     
     
     
130. WANG H, Chen Y, Wang X, Huang B, et al
     Germline mutations of Holliday junction resolvase genes in multiple primary malignancies involving lung cancer lead to PARP inhibitor sensitization.
     Clin Cancer Res. 2024 Feb 13. doi: 10.1158/1078-0432.CCR-22-3300.
     PubMed     Abstract available
     
     
     
131. VAN DE HAAR J, Mankor JM, Hummelink K, Monkhorst K, et al
     Combining genomic biomarkers to guide immunotherapy in non-small cell lung cancer.
     Clin Cancer Res. 2024 Feb 1. doi: 10.1158/1078-0432.CCR-23-4027.
     PubMed     Abstract available
     
     
     
132. LAKHANI NJ, Rasco D, Wang H, Men L, et al
     First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors.
     Clin Cancer Res. 2024;30:506-521.
     PubMed     Abstract available
     
     
     January 2024
133. PARRA ER, Zhang J, Duose DY, Gonzalez-Kozlova E, et al
     Multi-omics analysis reveals immune features associated with immunotherapy benefit in squamous cell lung cancer patients from Phase III Lung-MAP S1400I trial.
     Clin Cancer Res. 2024 Jan 26. doi: 10.1158/1078-0432.CCR-23-0251.
     PubMed     Abstract available
     
     
     
134. GUAN S, Chen X, Wei Y, Wang F, et al
     Germline USP36 mutation confers resistance to EGFR-TKIs by upregulating MLLT3 expression in non-small cell lung cancer patients.
     Clin Cancer Res. 2024 Jan 23. doi: 10.1158/1078-0432.CCR-23-2357.
     PubMed     Abstract available
     
     
     
135. KESARI S, Wagle N, Carrillo JA, Sharma A, et al
     Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma.
     Clin Cancer Res. 2024;30:323-333.
     PubMed     Abstract available
     
     
     
136. NG J, Cai L, Girard L, Prall OWJ, et al
     Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies.
     Clin Cancer Res. 2024 Jan 5:OF1-OF13. doi: 10.1158/1078-0432.CCR-23-2360.
     PubMed     Abstract available
     
     
     
137. NAKAMICHI S, Kubota K, Misumi T, Kondo T, et al
     Phase II study of durvalumab immediately after completion of chemoradiotherapy in unresectable stage III non-small-cell lung cancer: TORG1937 (DATE study).
     Clin Cancer Res. 2024 Jan 2. doi: 10.1158/1078-0432.CCR-23-2568.
     PubMed     Abstract available
     
     
     December 2023
138. LOPEZ DE RODAS M, Wang Y, Peng G, Gu J, et al
     Objective analysis and clinical significance of the spatial tumor infiltrating lymphocyte patterns in non-small cell lung cancer (NSCLC).
     Clin Cancer Res. 2023 Dec 21. doi: 10.1158/1078-0432.CCR-23-2457.
     PubMed     Abstract available
     
     
     
139. PASSIGLIA F, Righi L, Bironzo P, Listi A, et al
     Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell Lung Cancer harboring HRR mutations: interim results of the UNITO-001 phase 2 prospective trial.
     Clin Cancer Res. 2023 Dec 18. doi: 10.1158/1078-0432.CCR-23-2431.
     PubMed     Abstract available
     
     
     
140. BOUMELHA J, Molina-Arcas M, Downward J
     Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy.
     Clin Cancer Res. 2023;29:5012-5020.
     PubMed     Abstract available
     
     
     
141. HUMMELINK K, Tissier R, Bosch LJW, Krijgsman O, et al
     A dysfunctional T cell gene signature for predicting non-response to PD-1 blockade in non-small cell lung cancer that is suitable for routine clinical diagnostics.
     Clin Cancer Res. 2023 Dec 13. doi: 10.1158/1078-0432.CCR-23-1061.
     PubMed     Abstract available
     
     
     
142. ROLFO C, Russo A
     In search of lost biomarker for immunotherapy in small-cell lung cancer.
     Clin Cancer Res. 2023 Dec 12. doi: 10.1158/1078-0432.CCR-23-3087.
     PubMed     Abstract available
     
     
     
143. BESSEDE A, Peyraud F, Besse B, Cousin S, et al
     TROP2 is associated with primary resistance to immune checkpoint inhibition in patients with advanced non-small cell lung cancer.
     Clin Cancer Res. 2023 Dec 1. doi: 10.1158/1078-0432.CCR-23-2566.
     PubMed     Abstract available
     
     
     
144. VOKES NI, Galan Cobo A, Fernandez-Chas M, Molkentine D, et al
     ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC.
     Clin Cancer Res. 2023;29:4958-4972.
     PubMed     Abstract available
     
     
     November 2023
145. MURRAY JC, Sivapalan L, Hummelink K, Balan A, et al
     Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer.
     Clin Cancer Res. 2023 Nov 8. doi: 10.1158/1078-0432.CCR-23-1469.
     PubMed     Abstract available
     
     
     October 2023
146. HERBST RS, Blanke CD, Sigal EV
     Novel Approach to Accelerate Lung Cancer Research: LungMap and the Potential of Public-Private Partnerships.
     Clin Cancer Res. 2023 Oct 30. doi: 10.1158/1078-0432.CCR-23-2690.
     PubMed     Abstract available
     
     
     
147. ZHOU X, Zhou L, Yao Z, Huang M, et al
     Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naive Stage IV PD-L1+ Non-Small Cell Lung Cancer Patients.
     Clin Cancer Res. 2023;29:4098-4108.
     PubMed     Abstract available
     
     
     
148. PAZ-ARES L, Garassino MC, Chen Y, Reinmuth N, et al
     Durvalumab +/- tremelimumab + platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): outcomes by PD-L1 expression and tissue tumor mutational burden.
     Clin Cancer Res. 2023 Oct 6. doi: 10.1158/1078-0432.CCR-23-1689.
     PubMed     Abstract available
     
     
     September 2023
149. BESSEDE A, Peyraud F, Le Moulec S, Cousin S, et al
     Upregulation of Indoleamine 2,3-dioxygenase 1 in tumor cells and tertiary lymphoid structures is a hallmark of inflamed non-small cell lung cancer.
     Clin Cancer Res. 2023 Sep 26. doi: 10.1158/1078-0432.CCR-23-1928.
     PubMed     Abstract available
     
     
     
150. DIMOU A
     Time to Think About Human Leukocyte Antigen-Based Diagnostics in Lung Cancer?
     Clin Cancer Res. 2023 Sep 26. doi: 10.1158/1078-0432.CCR-23-2152.
     PubMed     Abstract available
     
     
     
151. SOLTA A, Boettiger K, Kovacs I, Lang C, et al
     Entinostat enhances the efficacy of chemotherapy in small cell lung cancer through S-phase arrest and decreased base excision repair.
     Clin Cancer Res. 2023 Sep 19. doi: 10.1158/1078-0432.CCR-23-1795.
     PubMed     Abstract available
     
     
     
152. CANTOR DJ, Aggarwal C
     Targeting KRAS-Mutated NSCLC: Novel TKIs and Beyond.
     Clin Cancer Res. 2023;29:3563-3565.
     PubMed     Abstract available
     
     
     
153. DUKE ES, Bradford D, Marcovitz M, Amatya AK, et al
     FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors.
     Clin Cancer Res. 2023;29:3573-3578.
     PubMed     Abstract available
     
     
     
154. ABEL ML, Takahashi N, Peer C, Redon CE, et al
     Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial.
     Clin Cancer Res. 2023;29:3603-3611.
     PubMed     Abstract available
     
     
     
155. PELLINI B, Madison RW, Childress M, Miller ST, et al
     Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer.
     Clin Cancer Res. 2023 Sep 13. doi: 10.1158/1078-0432.CCR-23-1578.
     PubMed     Abstract available
     
     
     
156. GRAY JE, Ahn MJ, Oxnard GR, Shepherd FA, et al
     Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA.
     Clin Cancer Res. 2023;29:3340-3351.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum